Suchergebnisse

A management plan for the boat seines, called sonsera, used in Catalonia to target sand eels (Gymanammodytes cicerelus and G. semisquamatus) and transparent gobies was drawn up in accordance with European Union rules. A Sand Eel Co-Management Committee was formally created with the specific mission of ensuring a sustainable fishery. The Committee is composed of public administrations, fishermen's associations, researchers and NGOs. The process has two phases: first, a comprehensive study of the fishery and subsequent advice for the establishment of a management plan and, second, the implementation and monitoring of the management plan. The study of the fishery included the analysis of the ecosystem impacts of the fishery (mainly stock status, impact on sensitive habitats and by-catch) and was carried out in the wider context of an adaptive co-management process to respond to the requirements of an ecosystem approach to fisheries. ; Se ha desarrollado un plan de gestión de acuerdo a las normas de la Unión Europea de la pesquería con arte de tiro desde embarcación, llamado "sonsera", que se utiliza en Cataluña para la pesca del lanzón (Gymanammodytes cicerelus y G. semisquamatus) y también de pequeños góbidos. Se creó formalmente un Comité de Cogestión con la misión específica de garantizar una pesca sostenible. El Comité está integrado por las administraciones públicas, asociaciones de pescadores, investigadores y organizaciones no gubernamentales. El proceso consta de dos fases: en primer lugar, un estudio exhaustivo de la pesquería y posterior asesoramiento para el establecimiento de un plan de gestión, y en segundo lugar, la aplicación y seguimiento del plan de gestión. El estudio de la pesquería ha incluido el análisis de los impactos ambientales de la pesca (principalmente el estado del stock, el impacto en hábitats sensibles y las capturas accesorias) y se ha llevado a cabo en el contexto más amplio de un proceso adaptativo de gestión conjunta para responder a los requisitos de un enfoque ecosistémico de la pesca.

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19. ; This work was supported by grants from the Government of Spain (PIE_INTRAMURAL_ LINEA 1 - 202020E079; PIE_INTRAMURAL_CSIC-202020E043). The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. We also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N Izquierdo-Useros has nonrestrictive funding from PharmaMar to study the antiviral effect of Plitidepsin. NJ Krogan was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, and P01AI063302); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between the University of California, San Francisco (UCSF), University of California, Berkley (UCB), and GlaxoSmithKline (GSK) (#133122P); by the Roddenberry Foundation, and gifts from QCRG philanthropic donors. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement #HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. This research was partly funded by Center for Research for Influenza Pathogenesis and Transmission (CRIPT), a National Institute of Allergy and Infectious Diseases (NIAID) supported Center of Excellence for Influenza Research and Response (CEIRS, contract # 75N93021C00014), by DARPA grant HR0011-19-2-0020, by supplements to NIAID grants U19AI142733, U19AI135972, and DoD grant W81XWH-20-1-0270, and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), and anonymous donors to A García-Sastre. S Yildiz received funding from a Swiss National Foundation Early Postdoc Mobility fellowship (P2GEP3_184202). ; Peer reviewed